- Home
- GNTA vs SER Comparison
GNTA vs SER Comparison
Compare GNTA & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | SER |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | Italy | United States |
| Employees | N/A | 13 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 19.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GNTA | SER |
|---|---|---|
| Price | $0.85 | $1.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 53.4K | ★ 80.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $134.46 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.71 | $1.42 |
| 52 Week High | $10.00 | $7.92 |
Technical Indicators
Market Signals| Indicator | GNTA | SER |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 36.51 |
| Support Level | $0.71 | N/A |
| Resistance Level | $1.70 | $1.86 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 17.75 | 21.32 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.